Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;66(10):e27869.
doi: 10.1002/pbc.27869. Epub 2019 Jun 21.

Insights into pediatric rhabdomyosarcoma research: Challenges and goals

Marielle E Yohe  1 , Christine M Heske  1 , Elizabeth Stewart  2 , Peter C Adamson  3 , Nabil Ahmed  4 , Cristina R Antonescu  5 , Eleanor Chen  6 , Natalie Collins  7 , Alan Ehrlich  8 , Rene L Galindo  9 , Berkley E Gryder  1 , Heidi Hahn  10 , Sharon Hammond  11 , Mark E Hatley  2 , Douglas S Hawkins  12 , Madeline N Hayes  13 , Andrea Hayes-Jordan  14 , Lee J Helman  15 , Simone Hettmer  16 , Myron S Ignatius  17 , Charles Keller  18 , Javed Khan  1 , David G Kirsch  19 , Corinne M Linardic  19 , Philip J Lupo  4 , Rossella Rota  20 , Jack F Shern  1 , Janet Shipley  21 , Sivasish Sindiri  1 , Stephen J Tapscott  22 , Christopher R Vakoc  23 , Leonard H Wexler  5 , David M Langenau  13
Affiliations
Review

Insights into pediatric rhabdomyosarcoma research: Challenges and goals

Marielle E Yohe et al. Pediatr Blood Cancer. 2019 Oct.

Abstract

Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.

Keywords: cancer biology; early-phase clinical trials; genomics; rhabdomyosarcoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Histopathology and Genomics of the RMS subtypes Representative H&E staining (top), Circos plots (middle), and schematics of the genomic drivers (bottom) of each of the three RMS subtypes, PAX-fusion negative RMS, spindle cell/sclerosing RMS and PAX-fusion positive RMS. Histology courtesy of C.R. Antonescu. Circos plots adapted from ,. In these plots, chromosomes 1–22 as well as the sex chromosomes are arrayed in a circle and arranged clockwise. The length of the chromosome in Mb is depicted outside each representation. Mutations for each tumor are indicated outside the chromosome number. Somatic single nucleotide variants (SNVs, blue), germline SNVs (gray), Tier 1 chromosomal translocations (translocations with strong clinical significance, green) and Tier 2 chromosomal translocations (translocations with potential clinical significance, orange) are shown. The outermost track of the Circos plot is a representation of the cytogenetic banding pattern of each chromosome, with the centromere colored red. For the spindle cell/sclerosing RMS tumor, somatic copy number alterations (aqua) are shown in the center track. In the innermost track, dots represent a somatic (blue) or germline (gray) SNV. The position of the dot within the track is representative of the variant allele frequency (VAF) for that SNV: SNVs with a higher VAF are positioned closer to the center of the Circos plot. In the center of the plot, lines link genes that are partners in Tier 1 (green) or Tier 2 (orange) translocations. In this figure, driver mutations for each RMS subtype are bolded (NRAS mutation, MYOD1 mutation and PAX3-FOXO1 translocation) are highlighted.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shern JF, Yohe ME, Khan J. Pediatric Rhabdomyosarcoma. Crit Rev Oncog 2015;20(3–4):227–243. - PMC - PubMed
    1. Kashi VP, Hatley ME, Galindo RL. Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nat Rev Cancer 2015;15(7):426–439. - PMC - PubMed
    1. Kikuchi K, Keller C. The not-so-skinny on muscle cancer. Cancer Cell 2012;22(4):421–422. - PMC - PubMed
    1. Missiaglia E, Williamson D, Chisholm J, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012;30(14):1670–1677. - PubMed
    1. Skapek SX, Anderson J, Barr FG, et al. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report. Pediatr Blood Cancer 2013;60(9):1411–1417. - PMC - PubMed

Publication types

LinkOut - more resources